{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:43:02Z","timestamp":1783226582946,"version":"3.54.6"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of anti-CD20 drugs has become a widespread therapeutic approach in systemic and central nervous system (CNS) neuroinflammation. Apart from the desired B-cell depletion, relevant dynamics of the humoral and cellular immune response occur. Despite the extensive utilization of these drugs, direct comparative analyses of various B-cell-depleting agents remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 262 patients with neuroimmunological diseases treated with ocrelizumab, ofatumumab, or rituximab were observed over a median period of 36 months. Relapses, infection rates, and the concentration of immunoglobulins were monitored quarterly. In addition, changes in cellular immunity (differential blood count, natural killer cells, CD19\n                      <jats:sup>+<\/jats:sup>\n                      , CD3\n                      <jats:sup>+<\/jats:sup>\n                      , CD4\n                      <jats:sup>+<\/jats:sup>\n                      , and CD8\n                      <jats:sup>+<\/jats:sup>\n                      cells) along with polyclonal T-cell function (measured by reactivity) were analyzed using multidimensional flow cytometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Annual relapse rates in both the ocrelizumab and ofatumumab groups were low: 0.11 [95 % confidence interval (CI), 0.06 \u2013 0.15] and 0.08 (95% CI, 0.05 \u2013 0.16), respectively. Infections occurred significantly less frequently with ofatumumab (p &amp;lt; 0.001). Hypogammaglobulinemia was observed more frequently and earlier in rituximab patients (p &amp;lt; 0.001). Ocrelizumab treatment was associated with a reduction in the proportion of total lymphocytes and an increase in the proportion of CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells, while ofatumumab was linked to a rise in the CD4\/CD8 ratio. Anti-CD20 antibodies did not influence T-cell reactivity after polyclonal stimulation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>B-cell depletion is effective in neuroimmunological diseases irrespective of which CD20 antibody was used. However, differences in infection rates and the occurrence of hypogammaglobulinemia were observed. Together with new insights into differences in the influence of CD20 antibodies on lymphocyte subpopulations, these findings may inform future individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1738865","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:29:18Z","timestamp":1778560158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort"],"prefix":"10.3389","volume":"17","author":[{"given":"Jakob","family":"St\u00f6gbauer","sequence":"first","affiliation":[{"name":"Department of Neurology, Saarland University Medical Center and Saarland University Faculty of Medicine","place":["Homburg, Germany"]},{"name":"Department of Neurology, Saarland University","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Bewarder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Saarland University Medical Center","place":["Homburg, Germany"]},{"name":"Center for Hematology and Oncology Bethanien","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gro\u00df","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saarland University Medical Center and Saarland University Faculty of Medicine","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Thurner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Saarland University Medical Center","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fassbender","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saarland University Medical Center and Saarland University Faculty of Medicine","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Urschel","sequence":"additional","affiliation":[{"name":"Department of Transplant and Infection Immunology, Saarland University","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar A.","family":"H\u00f8gest\u00f8l","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro O.","family":"Nygaard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne F.","family":"Harbo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sester","sequence":"additional","affiliation":[{"name":"Department of Transplant and Infection Immunology, Saarland University","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Groppa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saarland University Medical Center and Saarland University Faculty of Medicine","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Fousse","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saarland University Medical Center and Saarland University Faculty of Medicine","place":["Homburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002567","article-title":"Autoimmune encephalitis: clinical spectrum and management","volume":"21","author":"Uy","year":"2021","journal-title":"Pract Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pr\u00fcss","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.06.003","article-title":"New insights into B cells as antigen presenting cells","volume":"70","author":"Ghosh","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheumatic Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult Scler"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27012","article-title":"COMBAT-MS: A population-based observational cohort study addressing the benefit-risk balance of multiple sclerosis therapies compared with rituximab","volume":"96","author":"Piehl","year":"2024","journal-title":"Ann Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double\u2010blind placebo\u2010controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"A136","DOI":"10.1136\/jnnp-2022-ABN.438","article-title":"113 Benefit-risk of ofatumumab in treatment-na\u00efve early relapsing multiple sclerosis patients","volume":"93","author":"G\u00e4rtner","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51732","article-title":"Real\u2010world evaluation of ocrelizumab in multiple sclerosis: A systematic review","volume":"10","author":"Montalban","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00784-0","article-title":"Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis","volume":"14","author":"Hauser","year":"2025","journal-title":"Neurol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213574","article-title":"Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the phase 3 OCARINA II study","volume":"104","author":"Newsome","year":"2025","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult Scler"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06582-y","article-title":"Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"44","author":"Saidha","year":"2023","journal-title":"Neurol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cjn.2024.21","article-title":"Hypogammaglobulinemia and infection risk in an ocrelizumab-treated multiple sclerosis cohort","author":"Nobile","year":"2024","journal-title":"Can J Neurol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103740","article-title":"Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells","volume":"60","author":"Abbadessa","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cells14070552","article-title":"Effects of anti-CD20 antibody therapy on immune cell dynamics in relapsing-remitting multiple sclerosis","volume":"14","author":"Willison","year":"2025","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13920","article-title":"B-cell and T-cell populations in peripheral blood linked to ocrelizumab treatment efficacy in multiple sclerosis","volume":"39","author":"Akbayir","year":"2025","journal-title":"In Vivo"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-025-00486-x","article-title":"Long-term evaluation of effectiveness and immunological implications of ocrelizumab in a real-world cohort","volume":"12","author":"Guerra","year":"2025","journal-title":"Drugs Real World Outcomes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13075-018-1742-5","article-title":"VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs","volume":"20","author":"Schub","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-025-02766-3","article-title":"Efficacy of ocrelizumab versus rituximab in patients with relapsing-remitting multiple sclerosis","volume":"125","author":"Mounir","year":"2025","journal-title":"Acta Neurol Belg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27143","article-title":"Different treatment outcomes of multiple sclerosis patients receiving ocrelizumab or ofatumumab","volume":"97","author":"Meuth","year":"2025","journal-title":"Ann Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ana.78033","article-title":"Comparative safety profiles of ocrelizumab and rituximab in multiple sclerosis treatment using real\u2010World evidence","volume":"99","author":"Cerono","year":"2025","journal-title":"Ann Neurol"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-62703-601-6_19","article-title":"Detection of antigen-specific T cells based on intracellular cytokine staining using flow-cytometry","volume-title":"Virus-Host Interactions","author":"Schmidt","year":"2013"},{"key":"B34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12967-015-0420-5","article-title":"Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients","volume":"13","author":"Leyking","year":"2015","journal-title":"J Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200094","article-title":"Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J Comp Eff Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520952036","article-title":"De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis","volume":"27","author":"Disanto","year":"2021","journal-title":"Mult Scler"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult Scler"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J Neuroimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103798","article-title":"Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab","volume":"62","author":"Habek","year":"2022","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: A retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104400","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","volume":"68","author":"Peters","year":"2022","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09690-6","article-title":"Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis","volume":"268","author":"Schweitzer","year":"2021","journal-title":"J Neurol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab\u2010treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1500763","article-title":"Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study","volume":"15","author":"Aires Fernandes","year":"2024","journal-title":"Front Neurol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12537","article-title":"A multicentre, phase II trial of ofatumumab monotherapy in relapsed\/progressive diffuse large B\u2010cell lymphoma","volume":"163","author":"Coiffier","year":"2013","journal-title":"Br J Haematol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1177\/11795735241249644","article-title":"Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study","volume":"16","author":"Friedli","year":"2024","journal-title":"J Cent Nerv Syst Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi4632","article-title":"Proinflammatory CD20+ T cells contribute to CNS-directed autoimmunity","volume":"14","author":"Ochs","year":"2022","journal-title":"Sci Transl Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207291120","article-title":"Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity","volume":"120","author":"Shinoda","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01941","article-title":"T cell\/B cell collaboration and autoimmunity: An intimate relationship","volume":"9","author":"Petersone","year":"2018","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1738865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:29:19Z","timestamp":1778560159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1738865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2026.1738865"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1738865","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1738865"}}